PATENT CLAIM ANALYSIS

Application Number: 16176658
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-08
Patent Classification: ["424", "001890"]

Abstract:
The present invention provides an in vivo imaging method that facilitates the diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) at an early stage. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms. The present invention also provides methods for producing an in vivo imaging agent useful for early diagnosis of DIPG, where embodiments of the imaging agent include a lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety, and embodiments including [18F]FMISO as the lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety.

Claim (Index 46):
The method of  claim 44 , wherein said 18F-labelled compound is a compound selected from the group consisting of: 18F-fluoromisonidazole (18F-FMISO); and 1-H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole (18F-FMISO).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.61111
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14365725', '15526245', '13816589', '12448102', '10370092']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7528056966518103
- 35 USC 102 Novelty (BERT): 0.4676822369138939
- Combined Prediction Score: 0.7242933506780187
- Mean Citation Score: 159.51628
- Max Citation Score: 166.95502
- Similarity Product: 130.24848544042945

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test